PF-04457845
Jump to navigation
Jump to search
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status | |
Pharmacokinetic data | |
Metabolism | CY3A4 |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C23H20F3N5O2 |
Molar mass | 455.441 g·mol−1 |
3D model (JSmol) | |
| |
|
JZP150 (formerly PF-04457845) is an inhibitor of the enzyme fatty acid amide hydrolase (FAAH), with an IC50 of 7.2nM, and both analgesic and antiinflammatory effects in animal studies comparable to naproxen.[1]
JZP150 is currently being developed by Jazz Pharmaceuticals and is in a Phase 2 trial in the US for PTSD. Patients will be given 0.3mg orally once per day for up to 12 weeks, or 4.0mg orally once per day for up to 12 weeks, or a placebo.[2]
See also
- FAAH inhibitor
- 4-Nonylphenylboronic acid
- LY-2183240
- URB-597
- BIA 10-2474, problems in phase 1
References
- ^ Johnson DS, Stiff C, Lazerwith SE, Kesten SR, Fay LK, Morris M, et al. (February 2011). "Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor". ACS Medicinal Chemistry Letters. 2 (2): 91–96. doi:10.1021/ml100190t. PMC 3109749. PMID 21666860.
- ^ "A Study of JZP150 in Adults With Posttraumatic Stress Disorder - Full Text View - ClinicalTrials.gov". clinicaltrials.gov.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs not assigned an ATC code
- Infobox drug articles with non-default infobox title
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles containing unverified chemical infoboxes
- Enzyme inhibitors
- Trifluoromethyl compounds
- Pyridazines
- Pyridines